Cargando…
In Vitro and In Vivo Models for Evaluating the Oral Toxicity of Nanomedicines
Toxicity studies for conventional oral drug formulations are standardized and well documented, as required by the guidelines of administrative agencies such as the US Food & Drug Administration (FDA), the European Medicines Agency (EMA) or European Medicines Evaluation Agency (EMEA), and the Jap...
Autores principales: | Lama, Sudeep, Merlin-Zhang, Olivier, Yang, Chunhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694082/ https://www.ncbi.nlm.nih.gov/pubmed/33142878 http://dx.doi.org/10.3390/nano10112177 |
Ejemplares similares
-
Challenges to Safe Nanomedicine Treatment
por: Yang, Chunhua, et al.
Publicado: (2023) -
Nanoparticles for multimodal in vivo imaging in nanomedicine
por: Key, Jaehong, et al.
Publicado: (2014) -
Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies
por: Urbán, Patricia, et al.
Publicado: (2018) -
In Vivo Evaluation of the Oral Toxicity of the Chlorobutanol
por: Jeong, Dahye, et al.
Publicado: (2022) -
Nanomedicine for increasing the oral bioavailability of cancer treatments
por: Parodi, Alessandro, et al.
Publicado: (2021)